Epic Sciences announced an agreement with LabCorp to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development.
Epic Sciences announced an agreement with LabCorp to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development. Covance will process patient samples in Singapore, and then send samples to Epic's clinical laboratory in San Diego. This agreement expands on a previous contract announced last year between Epic and LabCorp for European clinical trials.
Epic's blood sample-based CTC technology can incorporate CTC enumeration, quantitative protein biomarker analysis and single-cell genomic analysis by next generation sequencing (NGS) or fluorescent in situ hybridization (FISH) to give a comprehensive picture of a patient's cancer. Its lab in San Diego was recently licensed under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, for downstream detection and molecular characterization of CTCs.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.